|
1
|
Thongprayoon C, Krambeck AE and Rule AD:
Determining the true burden of kidney stone disease. Nat Rev
Nephrol. 16:736–746. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buysschaert B, Aydin S, Morelle J, Gillion
V, Jadoul M and Demoulin N: Etiologies, clinical features, and
outcome of oxalate nephropathy. Kidney Int Rep. 5:1503–1509. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lumlertgul N, Siribamrungwong M, Jaber BL
and Susantitaphong P: Secondary oxalate nephropathy: A systematic
review. Kidney Int Rep. 3:1363–1372. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steiger S, Grill JF, Ma QY, Bäuerle T,
Jordan J, Smolle M, Böhland C, Lech M and Anders HJ:
Anti-transforming growth factor β IgG elicits a dual effect on CaOx
crystallization and progressive nephrocalcinosis-related chronic
kidney Disease. Front Immunol. 9:6192018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitchell T, Kumar P, Reddy T, Wood KD,
Knight J, Assimos DG and Holmes RP: Dietary oxalate and kidney
stone formation. Am J Physiol Renal Physiol. 316:409–413. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mulay SR and Anders HJ: Crystal
nephropathies: Mechanisms of crystal-induced kidney injury. Nat Rev
Nephrol. 13:226–240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Black LM, Lever JM and Agarwal A: Renal
inflammation and fibrosis: A double-edged sword. J Histochem
Cytochem. 67:663–681. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C
and Li B: Ferroptosis, a new form of cell death: Opportunities and
challenges in cancer. J Hematol Oncol. 12:342019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Derry PJ, Hegde ML, Jackson GR, Kayed R,
Tour JM, Tsai AL and Kent TA: Revisiting the intersection of
amyloid, pathologically modified tau and iron in Alzheimer's
disease from a ferroptosis perspective. Prog Neurobiol.
184:1017162020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Feng D, Wang Z, Zhao Y, Sun R, Tian
D, Liu D, Zhang F, Ning S, Yao J and Tian X: Ischemia-induced ACSL4
activation contributes to ferroptosis-mediated tissue injury in
intestinal ischemia/reperfusion. Cell Death Differ. 26:2284–2299.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Friedmann Angeli JP, Schneider M, Proneth
B, Tyurina YY, Tyurin VA, Hammond VJ, Herbach N, Aichler M, Walch
A, Eggenhofer E, et al: Inactivation of the ferroptosis regulator
Gpx4 triggers acute renal failure in mice. Nat Cell Biol.
16:1180–1191. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zilka O, Shah R, Li B, Friedmann Angeli
JP, Griesser M, Conrad M and Pratt DA: On the mechanism of
cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of
lipid peroxidation in ferroptotic cell death. ACS Cent Sci.
3:232–243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kajarabille N and Latunde-Dada GO:
Programmed cell-death by ferroptosis: Antioxidants as mitigators.
Int J Mol Sci. 20:49682019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin B, Wang Q, Lu Y, Li C, Hu H, Zhang J,
Wang Y, Zhu J, Zhu Y, Xun Y and Wang S: Losartan ameliorates
calcium oxalate-induced elevation of stone-related proteins in
renal tubular cells by inhibiting NADPH oxidase and oxidative
stress. Oxid Med Cell Longev. 2018:12718642018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Z, Zhang H, Yi B, Yang S, Liu J, Hu J,
Wang J, Cao K and Zhang W: VDR activation attenuate cisplatin
induced AKI by inhibiting ferroptosis. Cell Death Dis. 11:732020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song Q, Liao W, Chen X, He Z, Li D, Li B,
Liu J, Liu L, Xiong Y, Song C and Yang S: Oxalate activates
autophagy to induce ferroptosis of renal tubular epithelial cells
and participates in the formation of kidney stones. Oxid Med Cell
Longev. 2021:66303432021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chawla LS and Kimmel PL: Acute kidney
injury and chronic kidney disease: An integrated clinical syndrome.
Kidney Int. 82:516–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang F, Lv H, Zhao B, Zhou L, Wang S, Luo
J, Liu J and Shang P: Iron and leukemia: New insights for future
treatments. J Exp Clin Cancer Res. 38:4062019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Masaldan S, Belaidi AA, Ayton S and Bush
AI: Cellular senescence and iron dyshomeostasis in Alzheimer's
disease. Pharmaceuticals (Basel). 12:932019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alvarez SW, Sviderskiy VO, Terzi EM,
Papagiannakopoulos T, Moreira AL, Adams S, Sabatini DM, Birsoy K
and Possemato R: NFS1 undergoes positive selection in lung tumours
and protects cells from ferroptosis. Nature. 551:639–643. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang S and Xiao X: Ferroptosis and kidney
diseases. Int Urol Nephrol. 52:497–503. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miess H, Dankworth B, Gouw AM, Rosenfeldt
M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher
DW, et al: The glutathione redox system is essential to prevent
ferroptosis caused by impaired lipid metabolism in clear cell renal
cell carcinoma. Oncogene. 37:5435–5450. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miotto G, Rossetto M, Di Paolo ML, Orian
L, Venerando R, Roveri A, Vučković AM, Bosello Travain V, Zaccarin
M, Zennaro L, et al: Insight into the mechanism of ferroptosis
inhibition by ferrostatin-1. Redox Biol. 28:1013282020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Skouta R, Dixon SJ, Wang J, Dunn DE, Orman
M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A and
Stockwell BR: Ferrostatins inhibit oxidative lipid damage and cell
death in diverse disease models. J Am Chem Soc. 136:4551–4556.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khan SR: Reactive oxygen species as the
molecular modulators of calcium oxalate kidney stone formation:
Evidence from clinical and experimental investigations. J Urol.
189:803–811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu ZX, Zhang H, Yang SK, Wu XQ, He D, Cao
K and Zhang W: Emerging role of ferroptosis in acute kidney injury.
Oxid Med Cell Longev. 2019:80106142019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Liu Y, Wang Y and Sun L: The
cross-link between ferroptosis and kidney diseases. Oxid Med Cell
Longev. 2021:66548872021.PubMed/NCBI
|
|
29
|
Jiang GP, Liao YJ, Huang LL, Zeng XJ and
Liao XH: Effects and molecular mechanism of pachymic acid on
ferroptosis in renal ischemia reperfusion injury. Mol Med Rep.
23:632021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zou YL and Schreiber SL: Progress in
understanding ferroptosis and challenges in its targeting for
therapeutic benefit. Cell Chem Biol. 27:463–471. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang X and Li X: Abnormal iron and lipid
metabolism mediated ferroptosis in kidney diseases and its
therapeutic potential. Metabolites. 12:582022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Quan F, Cao Q, Lin Y, Yue C, Bi R,
Cui X, Yang H, Yang Y, Birnbaumer L, et al: Quercetin alleviates
acute kidney injury by inhibiting ferroptosis. J Adv Res.
28:231–243. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yaito Y, Fujii A, Sawada H, Oboshi M,
Iwasaku T, Okuhara Y, Morisawa D, Eguchi A, Hirotani S and Masuyama
T: Association between renal iron accumulation and renal
interstitial fibrosis in a rat model of chronic kidney disease.
Hypertens Res. 38:463–470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ikeda Y, Ozono I, Tajima S, Imao M,
Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K,
Tsuchiya K and Tamaki T: Iron chelation by deferoxamine prevents
renal interstitial fibrosis in mice with unilateral ureteral
obstruction. PLoS One. 9:e893552014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang L, Zhang Z, Li M, Wang F, Jia Y,
Zhang F, Shao J, Chen A and Zheng S: P53-dependent induction of
ferroptosis is required for artemether to alleviate carbon
tetrachloride-induced liver fibrosis and hepatic stellate cell
activation. IUBMB Life. 71:45–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Z, Yao Z, Wang L, Ding H, Shao J,
Chen A, Zhang F and Zheng S: Activation of ferritinophagy is
required for the RNA-binding protein ELAVL1/HuR to regulate
ferroptosis in hepatic stellate cells. Autophagy. 14:2083–2103.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong Y, Wang N, Liu N and Dong H: Lipid
peroxidation and GPX4 inhibition are common causes for
myofibroblast differentiation and ferroptosis. DNA Cell Biol.
38:725–733. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ye Z, Xia Y, Zhou X, Li B, Yu W, Ruan Y,
Li H, Ning J, Chen L, Rao T and Cheng F: CXCR4 inhibition
attenuates calcium oxalate crystal deposition-induced renal
fibrosis. Int Immunopharmacol. 107:1086772022. View Article : Google Scholar : PubMed/NCBI
|
